Abraham Weizman
Overview
Explore the profile of Abraham Weizman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
590
Citations
7063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Golubchik P, Weizman A
Clin Neuropharmacol
. 2025 Mar;
PMID: 40062954
Objectives: This cohort study aimed to better understand the relationship between attention deficit hyperactivity disorder (ADHD) severity predating the COVID-19 outbreak, in children with ADHD, and the severity of ADHD...
2.
Merzon E, Magen E, Levy Y, Ashkenazi S, Manor I, Weizman A, et al.
Children (Basel)
. 2024 Nov;
11(11).
PMID: 39594963
Pediatric pain significantly affects children's lives, leading to school absenteeism, impaired social interactions, and psychological distress. The perception of sensory signals as pain is influenced by the brain's noradrenergic system,...
3.
Merzon E, Farag R, Ashkenazi S, Magen E, Manor I, Weizman A, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458025
: Selective Immunoglobulin A Deficiency (SIgAD) is one of the most prevalent immunodeficiencies, characterized by an increased risk of mucosal infections. Attention deficit hyperactivity disorder (ADHD) is among the most...
4.
Obeid F, Kahana M, Dahle B, Monga S, Zohar Y, Weizman A, et al.
Cells
. 2024 Oct;
13(20.
PMID: 39451220
We assessed the anti-inflammatory activity of the TSPO ligand 2-Cl-MGV-1. Lipopolysaccharide (LPS) was used to induce inflammatory response in a murine RAW264.7 macrophage model (LPS: 100 ng/mL) and a mouse...
5.
Amitai M, Etedgi E, Mevorach T, Kalimi R, Horesh N, Oschry-Bernstein N, et al.
J Child Adolesc Psychopharmacol
. 2024 Sep;
34(9):407-413.
PMID: 39321142
Exposure to a range of stressful life events (SLE) is implicated in youth psychopathology. Previous studies point to a discrepancy between parents'/children's reports regarding stressful life events. No study systematically...
6.
Magen E, Geishin A, Weizman A, Merzon E, Green I, Magen I, et al.
Brain Behav Immun Health
. 2024 Sep;
40:100847.
PMID: 39252984
Background: Mood disorders (MD) are multifactorial disorders. Identifying new biomarkers for the early diagnosis of MD and predicting response to treatment is currently a significant research topic. Both eosinopenia and...
7.
Hess S, Yeshua M, Eisen A, Burnishev Y, Sultan E, Pell G, et al.
Brain Stimul
. 2024 Jul;
17(4):907-910.
PMID: 39069126
No abstract available.
8.
Shkalim Zemer V, Manor I, Weizman A, Cohen H, Hoshen M, Menkes Caspi N, et al.
Psychiatry Res
. 2024 Jul;
339:116077.
PMID: 39053214
Infection and lockdowns resulting from COVID-19 have been suggested to increase the prevalence and treatment rates of Attention Deficit/Hyperactivity Disorder (ADHD). To accurately estimate the pandemic's effects, pre-pandemic data can...
9.
Avrahami M, Ben-Dor D, Ratzon R, Weizman A, Danieli P
Glob Ment Health (Camb)
. 2024 Jun;
11:e63.
PMID: 38827333
The prevalence of autism spectrum disorder (ASD) is increasing worldwide. Youngsters with ASD demonstrate higher rates of intellectual disabilities (IDs), comorbid psychopathology and psychiatric hospitalizations, compared to children in the...
10.
Avrahami M, Liwinski T, Eckstein Z, Peskin M, Perlman P, Sarlon J, et al.
Psychopharmacology (Berl)
. 2024 May;
241(9):1883-1894.
PMID: 38733528
Rationale: Valproic acid (VPA) is commonly used as a second-line mood stabilizer or augmentative agent in severe mental illnesses. However, population pharmacokinetic studies specific to psychiatric populations are limited, and...